Overview
The goal of this trial is that using tadalafil plus low-intensity extracorporeal shockwave therapy (li-ESWT) is more effective than using tadalafil alone in improving erection rigidity and sexual function. The efficacy of the combination of li-ESWT and tadalafil has been confirmed by a number of studies, including in patients after radical prostatectomy. However, this method is still not a "first-line" method in young primary patients and its benefits in combination with drugs for these patients are not obvious.
The investigators assume that the combination of tadalafil plus low-intensity extracorporeal shockwave therapy (li-ESWT) will improve the subjective state of patients assessed by points of validated questionnaires and Number of successful intercourse per week.
Description
The aim of the study is to test the hypothesis that using tadalafil plus shockwave in primary patient with ED treatment in more effective in improving erection rigidity and sexual function, then using tadalafil alone.
Eligibility
Inclusion Criteria:• Age 20 to 45;
- Married or have had a permanent sex partner for at least 3 months;
- IIEF-5 questionnaire scores below 20
Exclusion Criteria:
- History of previous use of PDE-5 inhibitors or fSWT;
- Patients with diabetes mellitus;
- Patients after the radical prostatectomy or major pelvic surgery;
- Patients with a confirmed neurological disease that may have caused the ED (Multiple Sclerosis, Parkinson's Disease, spinal cord injury);
- Patients with contraindications to the use of PDE-5 inhibitors and/or fSWT;